[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1989

Psoriasis and Vitamin D3A Review of Our Experience

Author Affiliations

From the Departments of Geriatric Medicine (Dr Morimoto) and Dermatology (Dr Yoshikawa), Osaka University Medical School, Osaka, Japan.

Arch Dermatol. 1989;125(2):231-234. doi:10.1001/archderm.1989.01670140083015
Abstract

• Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D3) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D3 in both oral and topical ways in an opendesign study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1α,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D3 are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease.

(Arch Dermatol 1989;125:231-234)

×